DE1450454U - - Google Patents

Info

Publication number
DE1450454U
DE1450454U DENDAT1450454D DE1450454DU DE1450454U DE 1450454 U DE1450454 U DE 1450454U DE NDAT1450454 D DENDAT1450454 D DE NDAT1450454D DE 1450454D U DE1450454D U DE 1450454DU DE 1450454 U DE1450454 U DE 1450454U
Authority
DE
Germany
Prior art keywords
dte
dea
den
ç3tlete
xnspruoh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DENDAT1450454D
Other languages
German (de)
English (en)
Publication of DE1450454U publication Critical patent/DE1450454U/de
Active legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DENDAT1450454D Active DE1450454U (enExample)

Publications (1)

Publication Number Publication Date
DE1450454U true DE1450454U (enExample)

Family

ID=758234

Family Applications (1)

Application Number Title Priority Date Filing Date
DENDAT1450454D Active DE1450454U (enExample)

Country Status (1)

Country Link
DE (1) DE1450454U (enExample)

Similar Documents

Publication Publication Date Title
DE1450454U (enExample)
US6919370B2 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
Kumana et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies
Begley et al. Lenacapavir sustained delivery formulation supports 6-month dosing interval
DE2162701A1 (de) Bekleidungsstueck zum schutz gegen energiereiche projektile
Saunders et al. The State Records of North Carolina
Reynes et al. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals
Kanj et al. The battle against fungi: lessons in antifungal stewardship from COVID 19 times
Oikonomou et al. Liver disease in human immunodeficiency virus infection
Gathe Jr et al. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type 1-infected patients
Clay et al. Enthalpies of formation and solution of macrocyclic and noncyclic tetraaza ligands. Origins of the enthalpy term in the macrocyclic effect
Lee et al. Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma
Segal-Maurer et al. Potent antiviral activity of lenacapavir in phase 2/3 in heavily art-experienced PWH
GB973822A (en) Improvements relating to cubic boron nitride
Gaddoni et al. Contact dermatitis among decorators and enamellers in hand-made ceramic decorations.
Yamamoto et al. Effect of coadministration of uracil on the toxicity of tegafur
Neufeld et al. Biochemical Findings in Normal and Trauma-Resistant Rats Following Trauma.
Murskyj Disseminated histoplasmosis after vedolizumab treatment for ulcerative colitis
Woods et al. Methoclocinnamox: a μ partial agonist with pharmacotherapeutic potential for heroin abuse
Mccorquodale et al. Helicopter immobilization of elk in southcentral Washington
ES2304163T3 (es) Solucion inyectable esteril estable, lista para usar, de 9-((1,3-dihidroxipropan-2-iloxi)metil)-2-amina-1h-purin-6(9h)-ona; sistema cerrado para envasar solucion; procedim. eliminar residuos alcalinos cristales de 9-((1,3-dihidroxipropan-2-iloxi)metil)-2-amina-1h-purin-6(9h)-ona.
Prugnard et al. Chemistry and structure-activity relationships of biguanides
DE1487257U (enExample)
KR910016707A (ko) 5-페닐-1h-피라졸-4-프로피온산 유도체, 그 제조 및 사용방법.
CN213726562U (zh) 一种化学试剂助剂安全储存柜